M Evo Global Acquisition II, a blank check company targeting the critical minerals sector in the US, filed on Monday with the SEC to raise up to $225 million in an initial public offering. The company plans to raise $225 million by offering 22.5 million units...read more
Invea Therapeutics, a clinical-stage biotech developing oral small molecules for inflammatory diseases, filed on Monday with the SEC to raise up to $35 million in an initial public offering. Invea Therapeutics originally filed for an IPO in October 2023, but...read more
Medline (Nasdaq: MDLN) launched the biggest IPO since 2021. The PE-backed medical supplies giant plans to raise $5 billion to pay down debt. Just two other deals have raised that much in the past 10 years: Rivian (2021) and Uber (2019).
SPAC M Evo Global Acquisition II files for a $225 million IPO, targeting US critical minerals
M Evo Global Acquisition II, a blank check company targeting the critical minerals sector in the US, filed on Monday with the SEC to raise up to $225 million in an initial public offering. The company plans to raise $225 million by offering 22.5 million units...read more
Inflammatory disease biotech Invea Therapeutics refiles for a $35 million IPO
Invea Therapeutics, a clinical-stage biotech developing oral small molecules for inflammatory diseases, filed on Monday with the SEC to raise up to $35 million in an initial public offering. Invea Therapeutics originally filed for an IPO in October 2023, but...read more
US IPO Weekly Winners & Losers
Medline (Nasdaq: MDLN) launched the biggest IPO since 2021. The PE-backed medical supplies giant plans to raise $5 billion to pay down debt. Just two other deals have raised that much in the past 10 years: Rivian (2021) and Uber (2019).
It’s joined on
... read more